<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Pain Res Manag</journal-id><journal-id journal-id-type="iso-abbrev">Pain Res Manag</journal-id><journal-id journal-id-type="publisher-id">PRM</journal-id><journal-title-group><journal-title>Pain Research &amp; Management</journal-title></journal-title-group><issn pub-type="ppub">1203-6765</issn><issn pub-type="epub">1918-1523</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29623143</article-id><article-id pub-id-type="pmc">5830023</article-id><article-id pub-id-type="doi">10.1155/2018/3637013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Efficacy of Nalbuphine with Flurbiprofen on Multimodal Analgesia with Transverse Abdominis Plane Block in Elderly Patients Undergoing Open Gastrointestinal Surgery: A Randomized, Controlled, Double-Blinded Trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Mao</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cao</surname><given-names>Yuanyuan</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mei</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Lijian</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xuesheng</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhi</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5986-0599</contrib-id><name><surname>Gu</surname><given-names>Erwei</given-names></name><email>18019951656@163.com</email><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Key Laboratory of Brain Function and Disease of Chinese Academy of Science, Department of Biophysics and Neurobiology, University of Science and Technology of China, Hefei, Anhui 230027, China</aff><aff id="I2">
<sup>2</sup>Department of Anesthesiology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230031, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Andreas Sandner-Kiesling</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>28</day><month>1</month><year>2018</year></pub-date><volume>2018</volume><elocation-id>3637013</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>8</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>Copyright © 2018 Yu Mao et al.</copyright-statement><copyright-year>2018</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="3887" xml_f="3896" txt_i="11" txt_f="20">Objective</offsets></title><p><offsets xml_i="3907" xml_f="4145" txt_i="21" txt_f="259"> To assess different doses of nalbuphine with flurbiprofen compared to sufentanil with flurbiprofen in multimodal analgesia efficacy for elderly patients undergoing gastrointestinal surgery with a transverse abdominis plane block (TAPB). </offsets></p></sec><sec><title><offsets xml_i="4167" xml_f="4174" txt_i="261" txt_f="268">Methods</offsets></title><p><offsets xml_i="4185" xml_f="4583" txt_i="269" txt_f="667"> 158 elderly patients scheduling for elective open gastrointestinal surgery under general anesthesia and TAPB were randomly assigned to four groups according to different doses of nalbuphine with flurbiprofen in postoperative intravenous analgesia (PCIA). Postoperative pain intensity, effective pressing numbers of PCIA, and adverse effects were recorded at 6, 12, 24, and 48 hours after surgery. </offsets></p></sec><sec><title><offsets xml_i="4605" xml_f="4612" txt_i="669" txt_f="676">Results</offsets></title><p><offsets xml_i="4623" xml_f="4978" txt_i="677" txt_f="1032"> Postoperative pain intensity, effective pressing numbers, and the incidence of postoperative nausea and vomiting (PONV) were similar among the four groups after surgery, while the severity of PONV was decreased in Group L compared with Group S at 6, 12, and 48 h after surgery. No individual experienced pruritus, respiratory depression, or hypotension. </offsets></p></sec><sec><title><offsets xml_i="5000" xml_f="5011" txt_i="1034" txt_f="1045">Conclusions</offsets></title><p><offsets xml_i="5022" xml_f="5050" txt_i="1046" txt_f="1074"> Low dose of nalbuphine (15 </offsets><italic><offsets xml_i="5058" xml_f="5059" txt_i="1074" txt_f="1075">μ</offsets></italic><offsets xml_i="5068" xml_f="5072" txt_i="1075" txt_f="1079">g·kg</offsets><sup><offsets xml_i="5077" xml_f="5079" txt_i="1079" txt_f="1081">−1</offsets></sup><offsets xml_i="5085" xml_f="5088" txt_i="1081" txt_f="1084">·ml</offsets><sup><offsets xml_i="5093" xml_f="5095" txt_i="1084" txt_f="1086">−1</offsets></sup><offsets xml_i="5101" xml_f="5335" txt_i="1086" txt_f="1320">) combined with flurbiprofen is superior for elderly patients undergoing elective open gastrointestinal surgery with TAPB in terms of the efficient postoperative analgesia and decreased severity of PONV. This trial is registered with </offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02984865"><offsets xml_i="5426" xml_f="5437" txt_i="1320" txt_f="1331">NCT02984865</offsets></ext-link><offsets xml_i="5448" xml_f="5449" txt_i="1331" txt_f="1332">.</offsets></p></sec></abstract></article-meta></front><body><sec id="sec1"><title><offsets xml_i="5521" xml_f="5536" txt_i="1341" txt_f="1356">1. Introduction</offsets></title><p><offsets xml_i="5547" xml_f="5662" txt_i="1357" txt_f="1472">Abdominal surgeries have greater postoperative mortality and complications that are correlated with increased age [</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="5693" xml_f="5694" txt_i="1472" txt_f="1473">1</offsets></xref><offsets xml_i="5701" xml_f="5968" txt_i="1473" txt_f="1740">]. Especially, 75% of postoperative patients experience inadequate pain after gastrointestinal surgery, and uncontrolled postoperative pain prompts respiratory distress, delays wound healing, and a potentially eventual transition from acute to chronic pain problems [</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="5999" xml_f="6000" txt_i="1740" txt_f="1741">2</offsets></xref><offsets xml_i="6007" xml_f="6008" txt_i="1741" txt_f="1742">–</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="6039" xml_f="6040" txt_i="1742" txt_f="1743">4</offsets></xref><offsets xml_i="6047" xml_f="6184" txt_i="1743" txt_f="1880">]. Thus, it severely challenges the proper use of analgesics for elderly patients undergoing open gastrointestinal surgery to clinicians.</offsets></p><p><offsets xml_i="6191" xml_f="6476" txt_i="1881" txt_f="2166">Mu opioid receptor agonists are the most common analgesics for postoperative pain management; however, they have severely adverse effects such as pruritus, respiratory depression, postoperative nausea and vomiting (PONV), urinary retention, constipation, bradycardia, and hypotension [</offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="6507" xml_f="6508" txt_i="2166" txt_f="2167">5</offsets></xref><offsets xml_i="6515" xml_f="6712" txt_i="2167" txt_f="2364">], which increase postoperative morbidity and mortality in elderly patients mainly due to decreased physiologic reserves, age-related comorbidities, altered pharmacodynamics, and pharmacokinetics [</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="6743" xml_f="6744" txt_i="2364" txt_f="2365">6</offsets></xref><offsets xml_i="6751" xml_f="6753" txt_i="2365" txt_f="2367">, </offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="6784" xml_f="6785" txt_i="2367" txt_f="2368">7</offsets></xref><offsets xml_i="6792" xml_f="6957" txt_i="2368" txt_f="2533">]. Nalbuphine, a narcotic kappa receptor agonist and partial mu receptor antagonist, provides comparable analgesic efficacy to morphine by modulating visceral pain [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="6988" xml_f="6989" txt_i="2533" txt_f="2534">8</offsets></xref><offsets xml_i="6996" xml_f="7045" txt_i="2534" txt_f="2583">] but with fewer opioid-induced adverse effects [</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="7076" xml_f="7077" txt_i="2583" txt_f="2584">9</offsets></xref><offsets xml_i="7084" xml_f="7243" txt_i="2584" txt_f="2743">]. Unfortunately, limited data propose a putative promise of nalbuphine in the treatment of pain for elderly patients undergoing open gastrointestinal surgery.</offsets></p><p><offsets xml_i="7250" xml_f="7462" txt_i="2744" txt_f="2956">Importantly, multimodal analgesia is defined as combining analgesics with different mechanisms of action within the peripheral and central nervous system to maximize analgesic efficacy and minimize side effects [</offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="7494" xml_f="7496" txt_i="2956" txt_f="2958">10</offsets></xref><offsets xml_i="7503" xml_f="7679" txt_i="2958" txt_f="3134">]. Opioids plus nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with greater patient satisfaction and reduce opioid use with fewer opioid-induced adverse effects [</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="7711" xml_f="7713" txt_i="3134" txt_f="3136">11</offsets></xref><offsets xml_i="7720" xml_f="8085" txt_i="3136" txt_f="3501">]. Flurbiprofen axetil, a nonselective NSAID incorporated in lipid microspheres, has high affinity for inflammatory tissue and surgical incision sites to control postoperative pain by blocking cyclooxygenase. In addition, preoperative and postoperative administration of flurbiprofen reduced postoperative opioid consumption and decreased systemic proinflammation [</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="8117" xml_f="8119" txt_i="3501" txt_f="3503">12</offsets></xref><offsets xml_i="8126" xml_f="8666" txt_i="3503" txt_f="4043">]. However, the postoperative analgesic efficacy of nalbuphine in combination with flurbiprofen is not clear in the elderly patients undergoing open gastrointestinal surgery. Moreover, the transverse abdominis plane block (TAPB) is a relatively novel procedure for applying local anesthetics into the anatomic neurofascial space and provides analgesia to the skin, muscles of the anterior abdominal wall, and parietal peritoneum. Specifically, it offers a significantly prolonged duration of analgesia during the early postoperative stage [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="8698" xml_f="8700" txt_i="4043" txt_f="4045">13</offsets></xref><offsets xml_i="8707" xml_f="8709" txt_i="4045" txt_f="4047">, </offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="8741" xml_f="8743" txt_i="4047" txt_f="4049">14</offsets></xref><offsets xml_i="8750" xml_f="8809" txt_i="4049" txt_f="4108">], and reduces opioid consumption after abdominal surgery [</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="8841" xml_f="8843" txt_i="4108" txt_f="4110">15</offsets></xref><offsets xml_i="8850" xml_f="8944" txt_i="4110" txt_f="4204">], suggesting the potential use for elderly patients undergoing open gastrointestinal surgery.</offsets></p><p><offsets xml_i="8951" xml_f="9525" txt_i="4205" txt_f="4779">In the randomized, controlled, and double-blinded clinical trial, we investigate the postoperative analgesic efficacy and side effects of nalbuphine plus flurbiprofen compared to those of sufentanil plus flurbiprofen. Specifically, the study aimed to test the joint hypothesis that nalbuphine combined with flurbiprofen as postoperative analgesia will provide effective analgesia control and reduce side effects of postoperative opioid consumption compared with sufentanil added with flurbiprofen in elderly patients undergoing open gastrointestinal surgery based with TAPB.</offsets></p></sec><sec id="sec2"><title><offsets xml_i="9557" xml_f="9581" txt_i="4781" txt_f="4805">2. Materials and Methods</offsets></title><sec id="sec2.1"><title><offsets xml_i="9613" xml_f="9626" txt_i="4806" txt_f="4819">2.1. Protocol</offsets></title><p><offsets xml_i="9637" xml_f="9809" txt_i="4820" txt_f="4992">The search protocol was approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University (PJ-2016-09-05) and registered at ClinicalTrials.gov (</offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02984865"><offsets xml_i="9900" xml_f="9911" txt_i="4992" txt_f="5003">NCT02984865</offsets></ext-link><offsets xml_i="9922" xml_f="10303" txt_i="5003" txt_f="5384">; principal investigator: Yu Mao; registration: November 11, 2016). We conducted a randomized, controlled, and double-blinded clinical trial in elderly patients undergoing elective, open gastrointestinal surgery from December 2016 to June 2017 at a single site. This study report was prepared in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines [</offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="10335" xml_f="10337" txt_i="5384" txt_f="5386">16</offsets></xref><offsets xml_i="10344" xml_f="10346" txt_i="5386" txt_f="5388">, </offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="10378" xml_f="10380" txt_i="5388" txt_f="5390">17</offsets></xref><offsets xml_i="10387" xml_f="10389" txt_i="5390" txt_f="5392">].</offsets></p></sec><sec id="sec2.2"><title><offsets xml_i="10423" xml_f="10446" txt_i="5394" txt_f="5417">2.2. Study Participants</offsets></title><p><offsets xml_i="10457" xml_f="11212" txt_i="5418" txt_f="6173">Patients were included if they were aged 65 years or older, with an ASA physical status of I–III, and able to understand the study and communicate with the study team. Eligible surgical procedures included radical gastrectomy for gastric cancer, radical resection of rectal carcinoma, or colon cancer. Patients were interviewed before the day of surgery, and informed consent was obtained from each patient before entry into the study. Subjects were excluded if they had a serious coexisting disease (e.g., respiratory insufficiency, class II–IV organic heart disease, history of recent brain injury, and hepatic or renal impairment) or a history of multiple adverse drug reactions or an allergy to anesthetic drugs or prior treatment with the study drug.</offsets></p></sec><sec id="sec2.3"><title><offsets xml_i="11246" xml_f="11277" txt_i="6175" txt_f="6206">2.3. Randomization and Blinding</offsets></title><p><offsets xml_i="11288" xml_f="11949" txt_i="6207" txt_f="6868">The randomized numbers were generated in varying block sizes on a 1 : 1 : 1 : 1 ratio without restrictions to any of the four groups using computer and sealed in opaque envelopes by a research coordinator without involvement of further study. The anesthesia assistant got one envelope and prepared all the study solutions after consented participant was transferred to the operation room. The anesthesia assistant was not involved in the further study; patients and anesthesiologists performing anesthesia were blinded to the allocation. All study participants receiving postoperative intravenous analgesia (PCIA) are as follows: Group S (sufentanil): 25 (ng·kg</offsets><sup><offsets xml_i="11954" xml_f="11956" txt_i="6868" txt_f="6870">−1</offsets></sup><offsets xml_i="11962" xml_f="11965" txt_i="6870" txt_f="6873">·ml</offsets><sup><offsets xml_i="11970" xml_f="11972" txt_i="6873" txt_f="6875">−1</offsets></sup><offsets xml_i="11978" xml_f="12003" txt_i="6875" txt_f="6900">) sufentanil plus 1 mg·ml</offsets><sup><offsets xml_i="12008" xml_f="12010" txt_i="6900" txt_f="6902">−1</offsets></sup><offsets xml_i="12016" xml_f="12066" txt_i="6902" txt_f="6952"> flurbiprofen; Group L (low-dose nalbuphine): 15 (</offsets><italic><offsets xml_i="12074" xml_f="12075" txt_i="6952" txt_f="6953">μ</offsets></italic><offsets xml_i="12084" xml_f="12088" txt_i="6953" txt_f="6957">g·kg</offsets><sup><offsets xml_i="12093" xml_f="12095" txt_i="6957" txt_f="6959">−1</offsets></sup><offsets xml_i="12101" xml_f="12104" txt_i="6959" txt_f="6962">·ml</offsets><sup><offsets xml_i="12109" xml_f="12111" txt_i="6962" txt_f="6964">−1</offsets></sup><offsets xml_i="12117" xml_f="12141" txt_i="6964" txt_f="6988">)nalbuphine plus 1 mg·ml</offsets><sup><offsets xml_i="12146" xml_f="12148" txt_i="6988" txt_f="6990">−1</offsets></sup><offsets xml_i="12154" xml_f="12207" txt_i="6990" txt_f="7043"> flurbiprofen; Group M (medium-dose nalbuphine): 20 (</offsets><italic><offsets xml_i="12215" xml_f="12216" txt_i="7043" txt_f="7044">μ</offsets></italic><offsets xml_i="12225" xml_f="12229" txt_i="7044" txt_f="7048">g·kg</offsets><sup><offsets xml_i="12234" xml_f="12236" txt_i="7048" txt_f="7050">−1</offsets></sup><offsets xml_i="12242" xml_f="12245" txt_i="7050" txt_f="7053">·ml</offsets><sup><offsets xml_i="12250" xml_f="12252" txt_i="7053" txt_f="7055">−1</offsets></sup><offsets xml_i="12258" xml_f="12283" txt_i="7055" txt_f="7080">) nalbuphine plus 1 mg·ml</offsets><sup><offsets xml_i="12288" xml_f="12290" txt_i="7080" txt_f="7082">−1</offsets></sup><offsets xml_i="12296" xml_f="12351" txt_i="7082" txt_f="7137"> flurbiprofen; and Group H (high-dose nalbuphine): 25 (</offsets><italic><offsets xml_i="12359" xml_f="12360" txt_i="7137" txt_f="7138">μ</offsets></italic><offsets xml_i="12369" xml_f="12373" txt_i="7138" txt_f="7142">g·kg</offsets><sup><offsets xml_i="12378" xml_f="12380" txt_i="7142" txt_f="7144">−1</offsets></sup><offsets xml_i="12386" xml_f="12389" txt_i="7144" txt_f="7147">·ml</offsets><sup><offsets xml_i="12394" xml_f="12396" txt_i="7147" txt_f="7149">−1</offsets></sup><offsets xml_i="12402" xml_f="12427" txt_i="7149" txt_f="7174">) nalbuphine plus 1 mg·ml</offsets><sup><offsets xml_i="12432" xml_f="12434" txt_i="7174" txt_f="7176">−1</offsets></sup><offsets xml_i="12440" xml_f="12612" txt_i="7176" txt_f="7348"> flurbiprofen. The study solution of PCIA was mixed in 150 ml, and PCIA settings included a 2 ml bolus with a lockout interval of 15 min and a background infusion of 2 ml·h</offsets><sup><offsets xml_i="12617" xml_f="12619" txt_i="7348" txt_f="7350">−1</offsets></sup><offsets xml_i="12625" xml_f="12649" txt_i="7350" txt_f="7374"> without a loading dose.</offsets></p></sec><sec id="sec2.4"><title><offsets xml_i="12683" xml_f="12711" txt_i="7376" txt_f="7404">2.4. Preoperative Procedures</offsets></title><p><offsets xml_i="12722" xml_f="13066" txt_i="7405" txt_f="7749">Patients were transferred to the operating room without premedication and standard monitoring including arterial blood pressure, electrocardiogram (ECG), pulse oximetry, and bispectral index (BIS) (Vista; Aspect Medical Systems Inc., Norwood, Norfolk County, Massachusettes, USA) was applied in all individuals. Oxygen was given via mask and 5 </offsets><italic><offsets xml_i="13074" xml_f="13075" txt_i="7749" txt_f="7750">μ</offsets></italic><offsets xml_i="13084" xml_f="13134" txt_i="7750" txt_f="7800">g sufentanil was given prior to implementing TAPB.</offsets></p></sec><sec id="sec2.5"><title><offsets xml_i="13168" xml_f="13187" txt_i="7802" txt_f="7821">2.5. TAPB Technique</offsets></title><p><offsets xml_i="13198" xml_f="13701" txt_i="7822" txt_f="8325">The preoperative TAPB guided by ultrasound was performed by an experienced regional anesthesiologist under sterile conditions. 2% chlorhexidine solution was used to clean the skin and a 100 mm, 22-G needle (Stimuplex A, B-Braun Medical, Bethlehem, Pennsylvania, Germany) was inserted using an in-plane technique guided by a linear, high frequency ranging from 15 to 6 MHz ultrasound probe (M-Turbo®, SonoSite Inc., Brothell, WA, USA) covered with a sterile sheath (3M Tegaderm, St.Paul, Minnesota, USA).</offsets></p><p><offsets xml_i="13708" xml_f="14337" txt_i="8326" txt_f="8955">For lower abdominal surgery, the transducer was placed transversely in the region of the anterior axillary line between the costal margin and the iliac crest. Once the three muscular layers of the abdominal wall (the external oblique, the internal oblique, and the transverse abdominis muscle) were identified, the neurofascial plane between the internal oblique and the transverse abdominis muscle was recognized. For upper abdominal surgery, the probe was placed just oblique to the sagittal plane and inferior to the costal margin to identify the lateral border of rectus muscle and the medial border of transverse abdominis [</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="14369" xml_f="14371" txt_i="8955" txt_f="8957">18</offsets></xref><offsets xml_i="14378" xml_f="15227" txt_i="8957" txt_f="9806">]. Once the tip of the needle was placed into the neurofascial plane between the transverse abdominis and the internal oblique muscle or between the posterior rectus sheath and transverse abdominis, a small amount of fluid (1–2 ml saline) was injected to hydrodissect the appropriate plane. Then, local anesthetic (15 ml of 0.5% ropivacaine and 5 mg dexamethasone) was deposited into the fascial layer to separate the internal oblique and transverse abdominis muscles. The injection appeared as a dark oval under ultrasound. Bilateral TAPB was applied for midline incision. TAPB was considered successful when the surgical site was hypoalgesic or analgesic as measured with acupuncture pain detection 10 min after TAPB. Block failure was noted for patients when block success was not achieved after 30 min, and the data were deleted in the analysis.</offsets></p></sec><sec id="sec2.6"><title><offsets xml_i="15261" xml_f="15284" txt_i="9808" txt_f="9831">2.6. General Anesthesia</offsets></title><p><offsets xml_i="15295" xml_f="15648" txt_i="9832" txt_f="10185">A standardized general anesthesia in all participants was administrated by an anesthesiologist blinded to randomized allocation. Propofol was administrated using a target-controlled infusion (TCI) pump (Graseby 3500 Anesthesia Pump; Graseby Medical Ltd., United Kingdom) during the induction of anesthesia. After the initial target concentration of 1.0 </offsets><italic><offsets xml_i="15656" xml_f="15657" txt_i="10185" txt_f="10186">μ</offsets></italic><offsets xml_i="15666" xml_f="15733" txt_i="10186" txt_f="10253">g/ml was reached, the concentration was gradually increased by 0.3 </offsets><italic><offsets xml_i="15741" xml_f="15742" txt_i="10253" txt_f="10254">μ</offsets></italic><offsets xml_i="15751" xml_f="15755" txt_i="10254" txt_f="10258">g·ml</offsets><sup><offsets xml_i="15760" xml_f="15762" txt_i="10258" txt_f="10260">−1</offsets></sup><offsets xml_i="15768" xml_f="15821" txt_i="10260" txt_f="10310"> until the BIS value was &lt;60. Sufentanil (0.3–0.5 </offsets><italic><offsets xml_i="15829" xml_f="15830" txt_i="10310" txt_f="10311">μ</offsets></italic><offsets xml_i="15839" xml_f="15843" txt_i="10311" txt_f="10315">g·kg</offsets><sup><offsets xml_i="15848" xml_f="15850" txt_i="10315" txt_f="10317">−1</offsets></sup><offsets xml_i="15856" xml_f="15885" txt_i="10317" txt_f="10346"> and cisatracurium (0.2 mg·kg</offsets><sup><offsets xml_i="15890" xml_f="15892" txt_i="10346" txt_f="10348">−1</offsets></sup><offsets xml_i="15898" xml_f="16120" txt_i="10348" txt_f="10570">) was injected and followed by tracheal intubation. End-tidal carbon dioxide was continuously monitored after intubation. Tidal volume and ventilation rate were adjusted with 100 percent oxygen to maintain the end-tidal CO</offsets><sub><offsets xml_i="16125" xml_f="16126" txt_i="10570" txt_f="10571">2</offsets></sub><offsets xml_i="16132" xml_f="16279" txt_i="10571" txt_f="10718"> partial pressure of arterial blood at 35–45 mmHg. The TCI of propofol was continuously infused to maintain BIS values from 45 to 60, and 0.1 mg·kg</offsets><sup><offsets xml_i="16284" xml_f="16285" txt_i="10718" txt_f="10719">−</offsets></sup><offsets xml_i="16291" xml_f="16363" txt_i="10719" txt_f="10791">1 cisatracurium were intermittently injected according to need. 0.1–0.2 </offsets><italic><offsets xml_i="16371" xml_f="16372" txt_i="10791" txt_f="10792">μ</offsets></italic><offsets xml_i="16381" xml_f="16385" txt_i="10792" txt_f="10796">g·kg</offsets><sup><offsets xml_i="16390" xml_f="16392" txt_i="10796" txt_f="10798">−1</offsets></sup><offsets xml_i="16398" xml_f="16624" txt_i="10798" txt_f="11024"> sufentanil was titrated for analgesia, as needed, if heart rate (HR) and/or mean arterial pressure (MAP) increased by 20% above baseline during surgery. Flurbiprofen (50 mg, iv) was administered before skin incision, and 0.1 </offsets><italic><offsets xml_i="16632" xml_f="16633" txt_i="11024" txt_f="11025">μ</offsets></italic><offsets xml_i="16642" xml_f="16646" txt_i="11025" txt_f="11029">g·kg</offsets><sup><offsets xml_i="16651" xml_f="16653" txt_i="11029" txt_f="11031">−1</offsets></sup><offsets xml_i="16659" xml_f="16880" txt_i="11031" txt_f="11252"> sufentanil plus 50 mg flurbiprofen in group S or 0.1 mg/kg nalbuphine plus 50 mg flurbiprofen in L, M, and H groups were given intravenously followed by a PCIA pump just before the peritoneum was closed. Neostigmine (20 </offsets><italic><offsets xml_i="16888" xml_f="16889" txt_i="11252" txt_f="11253">μ</offsets></italic><offsets xml_i="16898" xml_f="16923" txt_i="11253" txt_f="11278">g/kg) and atropine (5–10 </offsets><italic><offsets xml_i="16931" xml_f="16932" txt_i="11278" txt_f="11279">μ</offsets></italic><offsets xml_i="16941" xml_f="17325" txt_i="11279" txt_f="11663">g/kg) were administrated intravenously to reverse residual muscle relaxation when spontaneous respiratory recovered at the end of surgery. Bradycardia or hypotension encountered during surgery or recovery was treated on the basis of the following algorithm: bradycardia (HR decreases by 20% from baseline), 0.2–0.3 mg IV atropine; hypotension (MAP decreases by 20% from baseline), 40 </offsets><italic><offsets xml_i="17333" xml_f="17334" txt_i="11663" txt_f="11664">μ</offsets></italic><offsets xml_i="17343" xml_f="17568" txt_i="11664" txt_f="11889">g IV phenylephrine; and bradycardia and hypotension, 3–6 mg IV ephedrine. All participants received the standard surgical procedures determined by the surgeons, and surgical management in the study was not altered in any way.</offsets></p></sec><sec id="sec2.7"><title><offsets xml_i="17602" xml_f="17631" txt_i="11891" txt_f="11920">2.7. Postoperative Management</offsets></title><p><offsets xml_i="17642" xml_f="18133" txt_i="11921" txt_f="12412">Patients were moved to the postanesthesia care unit (PACU) after surgery and extubated until they met extubation criteria. A bolus of intravenous analgesia of PCIA pump was allowed to give by a blinded PACU nursing staff when a 10 com visual analogue scale (VAS) value for pain exceeded 4. Patients were then transferred to wards when Steward Recovery Value exceeded 4. Patients were followed up by a nurse blinded to group allocations at 6, 12, 24, and 48 h as well as 7 days after surgery.</offsets></p></sec><sec id="sec2.8"><title><offsets xml_i="18167" xml_f="18188" txt_i="12414" txt_f="12435">2.8. Outcome Measures</offsets></title><p><offsets xml_i="18199" xml_f="18463" txt_i="12436" txt_f="12700">The primary outcome was the incidence of PONV at 6, 12, 24, and 48 h postoperatively. The degree of PONV was stratified as follows: 0, no nausea and vomiting; 1, mild; 2, moderate; 3, severe. Ondansetron (4 mg, iv) was given at the patient's request to treat PONV.</offsets></p><p><offsets xml_i="18470" xml_f="19152" txt_i="12701" txt_f="13383">Secondary outcomes included (1) a 10 cm VAS for pain (0, no pain; 10, worst imaginable pain); (2) effective pressing times of PCIA; (3) Ramsay sedation score (1, anxious, agitated, or restless; 2, cooperative, oriented, and tranquil; 3, responsive to command; 4, briskly responsive; 5, a sluggish response; 6, no response); (4) heart rate, noninvasive arterial pressure, respiratory rate, and oxygen saturation; (5) side effects (pruritus, respiratory depression, and hypotension) at 6, 12, 24, and 48 h postoperatively; and (6) short-time recovery (the first postoperative day for leaving the bed and intestinal movement, postoperative hospital duration, and hospitalization cost).</offsets></p><p><offsets xml_i="19159" xml_f="19787" txt_i="13384" txt_f="14006">Skin pruritus was recorded by incidence and diphenhydramine (25 mg, po) was given on demand. Respiratory depression was described as respiration &lt;8 bpm or oxygen saturation &lt;90%. Supplemental oxygen therapy was administrated to increase the fraction of inspired oxygen. PCIA would be stopped immediately if oxygen therapy was invalid. Naloxone (0.1 mg/kg) was available if needed to rescue respiration inhibition due to oversedation. IV fluids and closely monitoring were applied to treat hypotension defined as MAP decreased by 20% from baseline. PCIA would be stopped if blood pressure interventions were not successful.</offsets></p></sec><sec id="sec2.9"><title><offsets xml_i="19821" xml_f="19846" txt_i="14008" txt_f="14033">2.9. Statistical Analysis</offsets></title><p><offsets xml_i="19857" xml_f="20862" txt_i="14034" txt_f="15039">We aimed to test the joint hypothesis that nalbuphine with flurbiprofen, regardless of different dosages, provides effective postoperative analgesia and reduces side effects of postoperative analgesic consumption compared with sufentanil plus flurbiprofen in elderly patients experienced open gastrointestinal surgery with TAPB and to successively examine whether this multimodal strategy is an effective postoperative pain management with fewer side effects. Consequently, we started by comparing the PONV postoperatively, and sample size was calculated with previous data that were collected from 20 patients undergoing open gastrointestinal surgeries with general anesthesia-based TAPB using sufentanil and flurbiprofen as postoperative analgesia. The incidence of PONV 6 h after surgery was 0.35 in the previous study. Keeping a 5% type 1 error rate between groups and a study power of 80%, 31 subjects per group at a minimum were calculated to identify a difference of 0.25 at PONV 6 h after surgery.</offsets></p><p><offsets xml_i="20869" xml_f="21297" txt_i="15040" txt_f="15468">Data were analyzed using the Statistical Package for the Social Sciences program (SPSS 19.0). Quantitative data were presented as mean (SD) or mean (95% CI), and categorical data were showed as numbers or percentages. Quantitative data were analyzed using one-way ANOVA, and an LSD procedure was applied for post hoc comparisons. PONV severity and Ramsay sedation scale were assessed using a Kruskal–Wallis test. A Mann–Whitney </offsets><italic><offsets xml_i="21305" xml_f="21306" txt_i="15468" txt_f="15469">U</offsets></italic><offsets xml_i="21315" xml_f="21496" txt_i="15469" txt_f="15650"> test was used for intergroup comparisons when a significant difference was found among groups. The incidence of PONV was analyzed using a chi-square test or a Fisher's exact test (</offsets><italic><offsets xml_i="21504" xml_f="21505" txt_i="15650" txt_f="15651">p</offsets></italic><offsets xml_i="21514" xml_f="21649" txt_i="15651" txt_f="15783"> &lt; 0.05 was considered statistically significant). Bonferroni corrections were applied to correct for multiple comparisons testing (</offsets><italic><offsets xml_i="21657" xml_f="21658" txt_i="15783" txt_f="15784">p</offsets></italic><offsets xml_i="21667" xml_f="21720" txt_i="15784" txt_f="15834"> &lt; 0.01 was considered statistically significant).</offsets></p></sec></sec><sec id="sec3"><title><offsets xml_i="21758" xml_f="21768" txt_i="15837" txt_f="15847">3. Results</offsets></title><sec id="sec3.1"><title><offsets xml_i="21800" xml_f="21822" txt_i="15848" txt_f="15870">3.1. Participants Flow</offsets></title><p><offsets xml_i="21833" xml_f="21834" txt_i="15871" txt_f="15872">
</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="21866" xml_f="21874" txt_i="15872" txt_f="15880">Figure 1</offsets></xref><offsets xml_i="21881" xml_f="22501" txt_i="15880" txt_f="16500"> depicts the CONSORT flow of participants through the trial. 194 individuals were assessed for the eligibility of the study, of these 14 either disqualified for meeting exclusion criteria or individuals who met the inclusion criteria declined to participate in the study, 6 declined for other reasons. A total of 174 individuals were randomized: 43 were assigned to Group S, 45 to Group L, 42 to Group M, and 44 to Group H. 3 individuals in Group S, 5 in Group L, 4 in Group M, and 4 in Group H were excluded in the trial due to block failure or PCIA machine dysfunction, and 158 individuals finally completed the study.</offsets></p><p><offsets xml_i="22508" xml_f="22548" txt_i="16501" txt_f="16541">Basic subject characteristics appear in </offsets><xref ref-type="table" rid="tab1"><offsets xml_i="22582" xml_f="22589" txt_i="16541" txt_f="16548">Table 1</offsets></xref><offsets xml_i="22596" xml_f="23004" txt_i="16548" txt_f="16956">. There were no significant differences among groups in terms of gender, ASA, age, weight, height, BMI, and MAP. Anesthesia duration, operation time, consumption of sufentanil, crystalloid fluid infusion, and colloid fluid infusion during operation were not statistically significant different among groups, while awake time and extubation time during recovery were not significantly different among groups (</offsets><xref ref-type="table" rid="tab2"><offsets xml_i="23038" xml_f="23045" txt_i="16956" txt_f="16963">Table 2</offsets></xref><offsets xml_i="23052" xml_f="23054" txt_i="16963" txt_f="16965">).</offsets></p></sec><sec id="sec3.2"><title><offsets xml_i="23088" xml_f="23129" txt_i="16967" txt_f="17008">3.2. PCIA Requirements and Pain Intensity</offsets></title><p><offsets xml_i="23140" xml_f="23282" txt_i="17009" txt_f="17151">Effective PCIA machine pressure times and pain VAS data were not significantly different among the four groups during the observation period (</offsets><xref ref-type="table" rid="tab3"><offsets xml_i="23316" xml_f="23323" txt_i="17151" txt_f="17158">Table 3</offsets></xref><offsets xml_i="23330" xml_f="23433" txt_i="17158" txt_f="17261">). No patient experienced insufficient analgesia or treatment with adjunctive analgesics in this trial.</offsets></p></sec><sec id="sec3.3"><title><offsets xml_i="23467" xml_f="23499" txt_i="17263" txt_f="17295">3.3. PCIA-Related Adverse Events</offsets></title><p><offsets xml_i="23510" xml_f="23749" txt_i="17296" txt_f="17535">The incidence of postoperative nausea and vomiting was not significantly different among the four groups. PONV severity was significantly different among the four groups at 6, 12, and 48 h after surgery according to a Kruskal–Wallis test (</offsets><italic><offsets xml_i="23757" xml_f="23758" txt_i="17535" txt_f="17536">p</offsets></italic><offsets xml_i="23767" xml_f="23799" txt_i="17536" txt_f="17568">=0.002, 0.001, and0.029, resp.; </offsets><xref ref-type="table" rid="tab4"><offsets xml_i="23833" xml_f="23840" txt_i="17568" txt_f="17575">Table 4</offsets></xref><offsets xml_i="23847" xml_f="23956" txt_i="17575" txt_f="17684">). PONV severity was statically different in group S compared with group L at 6, 12, and 48 h after surgery (</offsets><italic><offsets xml_i="23964" xml_f="23965" txt_i="17684" txt_f="17685">p</offsets></italic><offsets xml_i="23974" xml_f="24070" txt_i="17685" txt_f="17781">1=0.002, 0.002, and0.006, resp.). The Ramsay scores of sedation were similar among four groups (</offsets><xref ref-type="table" rid="tab5"><offsets xml_i="24104" xml_f="24111" txt_i="17781" txt_f="17788">Table 5</offsets></xref><offsets xml_i="24118" xml_f="24362" txt_i="17788" txt_f="18032">). Only one patient in the group H reported that Ramsay score was 5 when assessed at 24 and 48 h, which resolved completely after the PCIA infusion finished. No patient experienced pruritus, respiratory depression, or hypotension in this study.</offsets></p></sec><sec id="sec3.4"><title><offsets xml_i="24396" xml_f="24434" txt_i="18034" txt_f="18072">3.4. Postoperative Short-Time Recovery</offsets></title><p><offsets xml_i="24445" xml_f="24620" txt_i="18073" txt_f="18248">The first day for bed-leaving activity and intestinal movement, postoperative hospital duration, and hospitalization expense were not significantly different among any group (</offsets><xref ref-type="table" rid="tab6"><offsets xml_i="24654" xml_f="24661" txt_i="18248" txt_f="18255">Table 6</offsets></xref><offsets xml_i="24668" xml_f="24670" txt_i="18255" txt_f="18257">).</offsets></p></sec></sec><sec id="sec4"><title><offsets xml_i="24708" xml_f="24721" txt_i="18260" txt_f="18273">4. Discussion</offsets></title><p><offsets xml_i="24732" xml_f="24831" txt_i="18274" txt_f="18373">Appropriate perioperative analgesia is a fundamental component of enhanced recovery after surgery [</offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="24863" xml_f="24865" txt_i="18373" txt_f="18375">19</offsets></xref><offsets xml_i="24872" xml_f="24874" txt_i="18375" txt_f="18377">, </offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="24906" xml_f="24908" txt_i="18377" txt_f="18379">20</offsets></xref><offsets xml_i="24915" xml_f="25189" txt_i="18379" txt_f="18653">]. Although epidural anesthesia is the standard care for postoperative pain, it has contraindications and limitations, such as spinal hematoma, epidural abscess, and hypotension and technical complications, especially for elderly patients who frequently take antiplatelets [</offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="25221" xml_f="25223" txt_i="18653" txt_f="18655">21</offsets></xref><offsets xml_i="25230" xml_f="25231" txt_i="18655" txt_f="18656">–</offsets><xref rid="B23" ref-type="bibr"><offsets xml_i="25263" xml_f="25265" txt_i="18656" txt_f="18658">23</offsets></xref><offsets xml_i="25272" xml_f="25470" txt_i="18658" txt_f="18856">]. A meta-analysis indicated that compared with alternative analgesic techniques, epidural analgesia did not provide additional clinical benefits to patients during laparoscopic colorectal surgery [</offsets><xref rid="B24" ref-type="bibr"><offsets xml_i="25502" xml_f="25504" txt_i="18856" txt_f="18858">24</offsets></xref><offsets xml_i="25511" xml_f="25653" txt_i="18858" txt_f="19000">]. TAPB is a novel and effective analgesia for controlling postoperative pain, and it can provide somatic anesthesia for abdominal surgeries [</offsets><xref rid="B25" ref-type="bibr"><offsets xml_i="25685" xml_f="25687" txt_i="19000" txt_f="19002">25</offsets></xref><offsets xml_i="25694" xml_f="25695" txt_i="19002" txt_f="19003">–</offsets><xref rid="B29" ref-type="bibr"><offsets xml_i="25727" xml_f="25729" txt_i="19003" txt_f="19005">29</offsets></xref><offsets xml_i="25736" xml_f="25875" txt_i="19005" txt_f="19144">]. It is important to note that the shortcoming of a single injection of local anesthetic is the limited time of regional neural blockade [</offsets><xref rid="B30" ref-type="bibr"><offsets xml_i="25907" xml_f="25909" txt_i="19144" txt_f="19146">30</offsets></xref><offsets xml_i="25916" xml_f="26087" txt_i="19146" txt_f="19317">]. Dexamethasone, yet not approved by FDA as an adjunct to local anesthetics, was still demonstrated to prolong the duration of analgesia after peripheral nerve blockade [</offsets><xref rid="B31" ref-type="bibr"><offsets xml_i="26119" xml_f="26121" txt_i="19317" txt_f="19319">31</offsets></xref><offsets xml_i="26128" xml_f="26218" txt_i="19319" txt_f="19409">]. Because the potential for toxicity is increased with higher doses of local anesthetic [</offsets><xref rid="B32" ref-type="bibr"><offsets xml_i="26250" xml_f="26252" txt_i="19409" txt_f="19411">32</offsets></xref><offsets xml_i="26259" xml_f="26261" txt_i="19411" txt_f="19413">, </offsets><xref rid="B33" ref-type="bibr"><offsets xml_i="26293" xml_f="26295" txt_i="19413" txt_f="19415">33</offsets></xref><offsets xml_i="26302" xml_f="26390" txt_i="19415" txt_f="19503">], 30 ml of 0.5% ropivacaine and 10 mg of dexamethasone as supported by the literature [</offsets><xref rid="B29" ref-type="bibr"><offsets xml_i="26422" xml_f="26424" txt_i="19503" txt_f="19505">29</offsets></xref><offsets xml_i="26431" xml_f="26433" txt_i="19505" txt_f="19507">, </offsets><xref rid="B33" ref-type="bibr"><offsets xml_i="26465" xml_f="26467" txt_i="19507" txt_f="19509">33</offsets></xref><offsets xml_i="26474" xml_f="26662" txt_i="19509" txt_f="19697">] was the maximum volume used in this study. No toxicity or adverse events were observed in elderly patients, suggesting that 30 ml of 0.5% ropivacaine and 10 mg dexamethasone can be safe.</offsets></p><p><offsets xml_i="26669" xml_f="26909" txt_i="19698" txt_f="19938">Even though successful TAPB can provide an effective anesthetic for abdominal somatalgia after surgery, it cannot provide complete postoperative analgesia for intraperitoneal surgeries, as it does not address pain in the abdominal viscera [</offsets><xref rid="B29" ref-type="bibr"><offsets xml_i="26941" xml_f="26943" txt_i="19938" txt_f="19940">29</offsets></xref><offsets xml_i="26950" xml_f="27067" txt_i="19940" txt_f="20057">]. NSAIDs modulate pain pathways by reducing local inflammation and preventing peripheral and central sensitization [</offsets><xref rid="B34" ref-type="bibr"><offsets xml_i="27099" xml_f="27101" txt_i="20057" txt_f="20059">34</offsets></xref><offsets xml_i="27108" xml_f="27305" txt_i="20059" txt_f="20256">]. When NSAIDs are administrated intravenously, they act as an adjunct regional blockade by suppressing prostaglandin E2 and cytokines in addition to inhibiting neural responses to noxious injury [</offsets><xref rid="B35" ref-type="bibr"><offsets xml_i="27337" xml_f="27339" txt_i="20256" txt_f="20258">35</offsets></xref><offsets xml_i="27346" xml_f="27536" txt_i="20258" txt_f="20448">]. Flurbiprofen injection encapsulated in lipid microspheres is a NSAID that decreases opioid consumption and offers better postoperative analgesia for patients after spinal fusion surgery [</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="27568" xml_f="27570" txt_i="20448" txt_f="20450">11</offsets></xref><offsets xml_i="27577" xml_f="27579" txt_i="20450" txt_f="20452">, </offsets><xref rid="B36" ref-type="bibr"><offsets xml_i="27611" xml_f="27613" txt_i="20452" txt_f="20454">36</offsets></xref><offsets xml_i="27620" xml_f="27674" txt_i="20454" txt_f="20508">]. Because NSAIDs pose a risk of anastomotic leakage [</offsets><xref rid="B37" ref-type="bibr"><offsets xml_i="27706" xml_f="27708" txt_i="20508" txt_f="20510">37</offsets></xref><offsets xml_i="27715" xml_f="27716" txt_i="20510" txt_f="20511">–</offsets><xref rid="B39" ref-type="bibr"><offsets xml_i="27748" xml_f="27750" txt_i="20511" txt_f="20513">39</offsets></xref><offsets xml_i="27757" xml_f="27905" txt_i="20513" txt_f="20661">], flurbiprofen should be given in low doses and combined with opioids to provide effective analgesia and decrease the risk of anastomotic leakage [</offsets><xref rid="B40" ref-type="bibr"><offsets xml_i="27937" xml_f="27939" txt_i="20661" txt_f="20663">40</offsets></xref><offsets xml_i="27946" xml_f="28041" txt_i="20663" txt_f="20758">]. Mu opioid receptor agonists act at the central nerve system and the gastrointestinal tract [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="28072" xml_f="28073" txt_i="20758" txt_f="20759">8</offsets></xref><offsets xml_i="28080" xml_f="28234" txt_i="20759" txt_f="20913">] and as such may be associated with adverse effects. Peripheral kappa opioid receptors, present in the visceral afferents of the gastrointestinal tract [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="28265" xml_f="28266" txt_i="20913" txt_f="20914">8</offsets></xref><offsets xml_i="28273" xml_f="28563" txt_i="20914" txt_f="21204">], are critical modulators of visceral pain. Nalbuphine agonizes the kappa receptor to mediate visceral pain and potentially antagonizes the mu receptor to attenuate adverse effects of mu agonists. Hence, nalbuphine is of interest as a compound that offers pain relief and few side effects.</offsets></p><p><offsets xml_i="28570" xml_f="28707" txt_i="21205" txt_f="21330">Potency at mu 1 and 2 and kappa receptors is sufentanil &gt; nalbuphine, sufentanil &gt; nalbuphine, and nalbuphine &gt;&gt; sufentanil [</offsets><xref rid="B41" ref-type="bibr"><offsets xml_i="28739" xml_f="28741" txt_i="21330" txt_f="21332">41</offsets></xref><offsets xml_i="28748" xml_f="28750" txt_i="21332" txt_f="21334">, </offsets><xref rid="B42" ref-type="bibr"><offsets xml_i="28782" xml_f="28784" txt_i="21334" txt_f="21336">42</offsets></xref><offsets xml_i="28791" xml_f="29061" txt_i="21336" txt_f="21606">]. Agonism at the mu 1 and 2 receptors produces analgesia and respiratory depression, respectively, and agonism at the kappa receptor produces analgesia and sedation. Therefore, nalbuphine is superior to morphine and offers comparable analgesia and few adverse effects [</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="29092" xml_f="29093" txt_i="21606" txt_f="21607">9</offsets></xref><offsets xml_i="29100" xml_f="29256" txt_i="21607" txt_f="21763">]. Because the analgesic potency of morphine is equivalent to that of nalbuphine, the ratio of an equipotent dose of sufentanil and nalbuphine is 1000 : 1 [</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="29287" xml_f="29288" txt_i="21763" txt_f="21764">9</offsets></xref><offsets xml_i="29295" xml_f="29297" txt_i="21764" txt_f="21766">, </offsets><xref rid="B43" ref-type="bibr"><offsets xml_i="29329" xml_f="29331" txt_i="21766" txt_f="21768">43</offsets></xref><offsets xml_i="29338" xml_f="29340" txt_i="21768" txt_f="21770">, </offsets><xref rid="B44" ref-type="bibr"><offsets xml_i="29372" xml_f="29374" txt_i="21770" txt_f="21772">44</offsets></xref><offsets xml_i="29381" xml_f="29455" txt_i="21772" txt_f="21846">]. In this study, sufentanil was delivered (iv, PCIA machine) at 25 (ng·kg</offsets><sup><offsets xml_i="29460" xml_f="29462" txt_i="21846" txt_f="21848">−1</offsets></sup><offsets xml_i="29468" xml_f="29471" txt_i="21848" txt_f="21851">·ml</offsets><sup><offsets xml_i="29476" xml_f="29478" txt_i="21851" txt_f="21853">−1</offsets></sup><offsets xml_i="29484" xml_f="29521" txt_i="21853" txt_f="21890">) to group S, and nalbuphine was 15 (</offsets><italic><offsets xml_i="29529" xml_f="29530" txt_i="21890" txt_f="21891">μ</offsets></italic><offsets xml_i="29539" xml_f="29543" txt_i="21891" txt_f="21895">g·kg</offsets><sup><offsets xml_i="29548" xml_f="29550" txt_i="21895" txt_f="21897">−1</offsets></sup><offsets xml_i="29556" xml_f="29559" txt_i="21897" txt_f="21900">·ml</offsets><sup><offsets xml_i="29564" xml_f="29566" txt_i="21900" txt_f="21902">−1</offsets></sup><offsets xml_i="29572" xml_f="29579" txt_i="21902" txt_f="21909">), 20 (</offsets><italic><offsets xml_i="29587" xml_f="29588" txt_i="21909" txt_f="21910">μ</offsets></italic><offsets xml_i="29597" xml_f="29601" txt_i="21910" txt_f="21914">g·kg</offsets><sup><offsets xml_i="29606" xml_f="29608" txt_i="21914" txt_f="21916">−1</offsets></sup><offsets xml_i="29614" xml_f="29617" txt_i="21916" txt_f="21919">·ml</offsets><sup><offsets xml_i="29622" xml_f="29624" txt_i="21919" txt_f="21921">−1</offsets></sup><offsets xml_i="29630" xml_f="29641" txt_i="21921" txt_f="21932">), and 25 (</offsets><italic><offsets xml_i="29649" xml_f="29650" txt_i="21932" txt_f="21933">μ</offsets></italic><offsets xml_i="29659" xml_f="29663" txt_i="21933" txt_f="21937">g·kg</offsets><sup><offsets xml_i="29668" xml_f="29670" txt_i="21937" txt_f="21939">−1</offsets></sup><offsets xml_i="29676" xml_f="29679" txt_i="21939" txt_f="21942">·ml</offsets><sup><offsets xml_i="29684" xml_f="29686" txt_i="21942" txt_f="21944">−1</offsets></sup><offsets xml_i="29692" xml_f="29779" txt_i="21944" txt_f="22031">) to L, M, and H groups, respectively. Our data reveal that low dose of nalbuphine (15 </offsets><italic><offsets xml_i="29787" xml_f="29788" txt_i="22031" txt_f="22032">μ</offsets></italic><offsets xml_i="29797" xml_f="29801" txt_i="22032" txt_f="22036">g·kg</offsets><sup><offsets xml_i="29806" xml_f="29808" txt_i="22036" txt_f="22038">−1</offsets></sup><offsets xml_i="29814" xml_f="29817" txt_i="22038" txt_f="22041">·ml</offsets><sup><offsets xml_i="29822" xml_f="29824" txt_i="22041" txt_f="22043">−1</offsets></sup><offsets xml_i="29830" xml_f="29922" txt_i="22043" txt_f="22135">) provides equivalent postoperative analgesia compared to high dose of sufentanil (25 n·g·kg</offsets><sup><offsets xml_i="29927" xml_f="29929" txt_i="22135" txt_f="22137">−1</offsets></sup><offsets xml_i="29935" xml_f="29938" txt_i="22137" txt_f="22140">·ml</offsets><sup><offsets xml_i="29943" xml_f="29945" txt_i="22140" txt_f="22142">−1</offsets></sup><offsets xml_i="29951" xml_f="30051" txt_i="22142" txt_f="22242">), likely because kappa receptor agonism blocking visceral pain is better than mu receptor agonism [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="30082" xml_f="30083" txt_i="22242" txt_f="22243">8</offsets></xref><offsets xml_i="30090" xml_f="30092" txt_i="22243" txt_f="22245">, </offsets><xref rid="B45" ref-type="bibr"><offsets xml_i="30124" xml_f="30126" txt_i="22245" txt_f="22247">45</offsets></xref><offsets xml_i="30133" xml_f="30281" txt_i="22247" txt_f="22395">]. Increasing the nalbuphine does not increase the analgesic efficacy, suggesting a ceiling effect for analgesia as well as respiratory depression [</offsets><xref rid="B43" ref-type="bibr"><offsets xml_i="30313" xml_f="30315" txt_i="22395" txt_f="22397">43</offsets></xref><offsets xml_i="30322" xml_f="30452" txt_i="22397" txt_f="22527">]. PONV is as high as 20–30% of the general surgical population, and postoperative opioids consumption is a risk factor for PONV [</offsets><xref rid="B46" ref-type="bibr"><offsets xml_i="30484" xml_f="30486" txt_i="22527" txt_f="22529">46</offsets></xref><offsets xml_i="30493" xml_f="30582" txt_i="22529" txt_f="22618">]. Even though the mechanism of PONV occurring after mu receptor agonist use is unclear [</offsets><xref rid="B47" ref-type="bibr"><offsets xml_i="30614" xml_f="30616" txt_i="22618" txt_f="22620">47</offsets></xref><offsets xml_i="30623" xml_f="30625" txt_i="22620" txt_f="22622">, </offsets><xref rid="B48" ref-type="bibr"><offsets xml_i="30657" xml_f="30659" txt_i="22622" txt_f="22624">48</offsets></xref><offsets xml_i="30666" xml_f="30928" txt_i="22624" txt_f="22886">], the severity of PONV is significantly decreased in group L compared with group S at 6, 12, and 48 h after surgery. Therefore, low dose of nalbuphine is better than high dose of sufentanil with equivalent postoperative analgesia and decreased severity of PONV.</offsets></p><p><offsets xml_i="30935" xml_f="31051" txt_i="22887" txt_f="23003">It should be noted that 10–50% of patients treated with intravenous opioids acquired opioid-induced pruritus (OIP) [</offsets><xref rid="B49" ref-type="bibr"><offsets xml_i="31083" xml_f="31085" txt_i="23003" txt_f="23005">49</offsets></xref><offsets xml_i="31092" xml_f="31192" txt_i="23005" txt_f="23105">] and 1.1% of patients receiving postoperative opioid analgesia experienced respiratory depression [</offsets><xref rid="B50" ref-type="bibr"><offsets xml_i="31224" xml_f="31226" txt_i="23105" txt_f="23107">50</offsets></xref><xref rid="B51" ref-type="bibr"><offsets xml_i="31265" xml_f="31267" txt_i="23107" txt_f="23109">51</offsets></xref><offsets xml_i="31274" xml_f="31440" txt_i="23109" txt_f="23275">], Group S outcomes may be due to low-dose sufentanil with TAPB. Because nalbuphine antagonizes the mu receptor, it is recommended as a first-line treatment for OIP [</offsets><xref rid="B47" ref-type="bibr"><offsets xml_i="31472" xml_f="31474" txt_i="23275" txt_f="23277">47</offsets></xref><offsets xml_i="31481" xml_f="31574" txt_i="23277" txt_f="23370">], and respiratory depression was not noted at any dose of nalbuphine during the observation.</offsets></p><p><offsets xml_i="31581" xml_f="31772" txt_i="23371" txt_f="23562">In summary, using multimodal analgesia with TAPB for elderly patients undergoing gastrointestinal surgery, we demonstrated that the optimal combination for PCIA is low dose of nalbuphine (15 </offsets><italic><offsets xml_i="31780" xml_f="31781" txt_i="23562" txt_f="23563">μ</offsets></italic><offsets xml_i="31790" xml_f="31794" txt_i="23563" txt_f="23567">g·kg</offsets><sup><offsets xml_i="31799" xml_f="31801" txt_i="23567" txt_f="23569">−1</offsets></sup><offsets xml_i="31807" xml_f="31810" txt_i="23569" txt_f="23572">·ml</offsets><sup><offsets xml_i="31815" xml_f="31817" txt_i="23572" txt_f="23574">−1</offsets></sup><offsets xml_i="31823" xml_f="31850" txt_i="23574" txt_f="23601">) and flurbiprofen (1 mg·ml</offsets><sup><offsets xml_i="31855" xml_f="31857" txt_i="23601" txt_f="23603">−1</offsets></sup><offsets xml_i="31863" xml_f="32135" txt_i="23603" txt_f="23875">) to minimize severity of PONV compared to PCIA with sufentanil and flurbiprofen after surgery. This study may provide a novel and optical option of multimodal analgesia for enhanced recovery in elderly patients undergoing gastrointestinal surgery with fewer side effects.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to acknowledge Xingmei Tian and Xunqin Liu for their invaluable assistance.</p></ack><sec><title>Authors' Contributions</title><p>Yu Mao, Yuanyuan Cao, Bin Mei, Xuesheng Liu, and Erwei Gu were responsible for study design and planning. Yu Mao and Lijian Chen were responsible for study conduct. Yu Mao and Zhi Zhang performed data analysis. Yu Mao and Zhi Zhang wrote the paper. All authors participated in revision of the paper.</p></sec><sec><title>Conflicts of Interest</title><p>The authors declare that there are no conflicts of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massarweh</surname><given-names>N. N.</given-names></name><name><surname>Legner</surname><given-names>V. J.</given-names></name><name><surname>Symons</surname><given-names>R. G.</given-names></name><name><surname>McCormick</surname><given-names>W. C.</given-names></name><name><surname>Flum</surname><given-names>D. R.</given-names></name></person-group><article-title>Impact of advancing age on abdominal surgical outcomes</article-title><source><italic>Archives of Surgery</italic></source><year>2009</year><volume>144</volume><issue>12</issue><fpage>1108</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1001/archsurg.2009.204</pub-id><pub-id pub-id-type="other">2-s2.0-73149120003</pub-id><pub-id pub-id-type="pmid">20026827</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filos</surname><given-names>K. S.</given-names></name><name><surname>Lehmann</surname><given-names>K. A.</given-names></name></person-group><article-title>Current concepts and practice in postoperative pain management: need for a change?</article-title><source><italic>European Surgical Research</italic></source><year>1999</year><volume>31</volume><issue>2</issue><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1159/000008627</pub-id><pub-id pub-id-type="other">2-s2.0-0032925741</pub-id><pub-id pub-id-type="pmid">10213847</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van de Ven</surname><given-names>T. J.</given-names></name><name><surname>Hsia</surname><given-names>H. L. J.</given-names></name></person-group><article-title>Causes and prevention of chronic postsurgical pain</article-title><source><italic>Current Opinion in Critical Care</italic></source><year>2012</year><volume>18</volume><issue>4</issue><fpage>366</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1097/MCC.0b013e3283557a7f</pub-id><pub-id pub-id-type="other">2-s2.0-84863844933</pub-id><pub-id pub-id-type="pmid">22732437</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hingula</surname><given-names>L.</given-names></name><name><surname>Maslin</surname><given-names>B.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Perioperative pain control in gastrointestinal surgery</article-title><source><italic>Middle East Journal of Anaesthesiology</italic></source><year>2015</year><volume>23</volume><issue>2</issue><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">26442389</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akshat</surname><given-names>S.</given-names></name><name><surname>Ramachandran</surname><given-names>R.</given-names></name><name><surname>Rewari</surname><given-names>V.</given-names></name><name><surname>Chandralekha</surname></name><name><surname>Trikha</surname><given-names>A.</given-names></name><name><surname>Sinha</surname><given-names>R.</given-names></name></person-group><article-title>Morphine versus nalbuphine for open gynaecological surgery: a randomized controlled double blinded trial</article-title><source><italic>Pain Research and Treatment</italic></source><year>2014</year><volume>2014</volume><fpage>6</fpage><pub-id pub-id-type="publisher-id">727952</pub-id><pub-id pub-id-type="doi">10.1155/2014/727952</pub-id><pub-id pub-id-type="other">2-s2.0-84900026567</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoelting</surname><given-names>R. K.</given-names></name><name><surname>Weinger</surname><given-names>M. B.</given-names></name></person-group><article-title>Dangers of postoperative opioids: is there a cure?</article-title><source><italic>Bulletin of the American College of Surgeons</italic></source><year>2010</year><volume>95</volume><issue>2</issue><fpage>21</fpage><lpage>22</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freye</surname><given-names>E.</given-names></name><name><surname>Levy</surname><given-names>J. V.</given-names></name></person-group><article-title>Use of opioids in the elderly–pharmacokinetic and pharmacodynamic considerations</article-title><source><italic>Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie: AINS</italic></source><year>2004</year><volume>39</volume><fpage>527</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1055/s-2004-825883</pub-id><pub-id pub-id-type="other">2-s2.0-4544360761</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>M. P.</given-names></name></person-group><article-title>Drug management of visceral pain: concepts from basic research</article-title><source><italic>Pain Research and Treatment</italic></source><year>2012</year><volume>2012</volume><fpage>18</fpage><pub-id pub-id-type="publisher-id">265605</pub-id><pub-id pub-id-type="doi">10.1155/2012/265605</pub-id><pub-id pub-id-type="other">2-s2.0-84868673423</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Shu</surname><given-names>C.</given-names></name><etal></etal></person-group><article-title>A comparision of nalbuphine with morphine for analgesic effects and safety : meta-analysis of randomized controlled trials</article-title><source><italic>Scientific Reports</italic></source><year>2015</year><volume>5</volume><issue>1</issue><fpage>p. 10927</fpage><pub-id pub-id-type="doi">10.1038/srep10927</pub-id><pub-id pub-id-type="other">2-s2.0-84930684542</pub-id><pub-id pub-id-type="pmid">26039709</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumann</surname><given-names>R.</given-names></name><name><surname>Shikora</surname><given-names>S.</given-names></name><name><surname>Weiss</surname><given-names>J. M.</given-names></name><name><surname>Wurm</surname><given-names>H.</given-names></name><name><surname>Strassels</surname><given-names>S.</given-names></name><name><surname>Carr</surname><given-names>D. B.</given-names></name></person-group><article-title>A comparison of multimodal perioperative analgesia to epidural pain management after gastric bypass surgery</article-title><source><italic>Anesthesia &amp; Analgesia</italic></source><year>2003</year><volume>96</volume><issue>2</issue><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1097/00000539-200302000-00032</pub-id><pub-id pub-id-type="other">2-s2.0-0037303204</pub-id><pub-id pub-id-type="pmid">12538198</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A.</given-names></name><name><surname>Bah</surname><given-names>M.</given-names></name></person-group><article-title>NSAIDs in the treatment of postoperative pain</article-title><source><italic>Current Pain and Headache Reports</italic></source><year>2016</year><volume>20</volume><issue>11</issue><fpage>p. 62</fpage><pub-id pub-id-type="doi">10.1007/s11916-016-0591-7</pub-id><pub-id pub-id-type="other">2-s2.0-84995630336</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>W.</given-names></name><name><surname>Hong</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><etal></etal></person-group><article-title>Flurbiprofen axetil enhances analgesic effects of sufentanil and attenuates postoperative emergence agitation and systemic proinflammation in patients undergoing tangential excision surgery</article-title><source><italic>Mediators of Inflammation</italic></source><year>2015</year><volume>2015</volume><fpage>6</fpage><pub-id pub-id-type="publisher-id">601083</pub-id><pub-id pub-id-type="doi">10.1155/2015/601083</pub-id><pub-id pub-id-type="other">2-s2.0-84939183892</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lissauer</surname><given-names>J.</given-names></name><name><surname>Mancuso</surname><given-names>K.</given-names></name><name><surname>Merritt</surname><given-names>C.</given-names></name><name><surname>Prabhakar</surname><given-names>A.</given-names></name><name><surname>Kaye</surname><given-names>A. D.</given-names></name><name><surname>Urman</surname><given-names>R. D.</given-names></name></person-group><article-title>Evolution of the transversus abdominis plane block and its role in postoperative analgesia</article-title><source><italic>Best Practice &amp; Research Clinical Anaesthesiology</italic></source><year>2014</year><volume>28</volume><issue>2</issue><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.bpa.2014.04.001</pub-id><pub-id pub-id-type="other">2-s2.0-84901896778</pub-id><pub-id pub-id-type="pmid">24993433</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kartalov</surname><given-names>A.</given-names></name><name><surname>Jankulovski</surname><given-names>N.</given-names></name><name><surname>Kuzmanovska</surname><given-names>B.</given-names></name><etal></etal></person-group><article-title>Effect of adding dexamethasone as a ropivacaine adjuvant in ultrasound-guided transversus abdominis plane block for inguinal hernia repair</article-title><source><italic>Prilozi (Makedonska akademija na naukite i umetnostite Oddelenie za medicinski nauki)</italic></source><year>2015</year><volume>36</volume><issue>3</issue><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1515/prilozi-2015-0076</pub-id><pub-id pub-id-type="other">2-s2.0-84984849173</pub-id><pub-id pub-id-type="pmid">27442394</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garimella</surname><given-names>V.</given-names></name><name><surname>Cellini</surname><given-names>C.</given-names></name></person-group><article-title>Postoperative pain control</article-title><source><italic>Clinics in Colon and Rectal Surgery</italic></source><year>2013</year><volume>26</volume><issue>3</issue><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1055/s-0033-1351138</pub-id><pub-id pub-id-type="other">2-s2.0-84882763962</pub-id><pub-id pub-id-type="pmid">24436674</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D.</given-names></name><name><surname>Hopewell</surname><given-names>S.</given-names></name><name><surname>Schulz</surname><given-names>K. F.</given-names></name><etal></etal></person-group><article-title>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</article-title><source><italic>International Journal of Surgery</italic></source><year>2012</year><volume>10</volume><issue>1</issue><fpage>28</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2011.10.001</pub-id><pub-id pub-id-type="other">2-s2.0-84856235433</pub-id><pub-id pub-id-type="pmid">22036893</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>K. F.</given-names></name><name><surname>Altman</surname><given-names>D. G.</given-names></name><name><surname>Moher</surname><given-names>D.</given-names></name></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title><source><italic>International Journal of Surgery</italic></source><year>2011</year><volume>9</volume><issue>8</issue><fpage>672</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2011.09.004</pub-id><pub-id pub-id-type="other">2-s2.0-83155184631</pub-id><pub-id pub-id-type="pmid">22019563</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>R.</given-names><suffix>Jr.</suffix></name><name><surname>Pergolizzi</surname><given-names>J. V.</given-names></name><name><surname>Sinclair</surname><given-names>A.</given-names></name><etal></etal></person-group><article-title>Transversus abdominis block: clinical uses, side effects, and future perspectives</article-title><source><italic>Pain Practice</italic></source><year>2013</year><volume>13</volume><issue>4</issue><fpage>332</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1111/j.1533-2500.2012.00595.x</pub-id><pub-id pub-id-type="other">2-s2.0-84875955401</pub-id><pub-id pub-id-type="pmid">22967210</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>U. O.</given-names></name><name><surname>Scott</surname><given-names>M. J.</given-names></name><name><surname>Schwenk</surname><given-names>W.</given-names></name><etal></etal></person-group><article-title>Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations</article-title><source><italic>Clinical Nutrition</italic></source><year>2012</year><volume>31</volume><issue>6</issue><fpage>783</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2012.08.013</pub-id><pub-id pub-id-type="other">2-s2.0-84870251357</pub-id><pub-id pub-id-type="pmid">23099039</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nygren</surname><given-names>J.</given-names></name><name><surname>Thacker</surname><given-names>J.</given-names></name><name><surname>Carli</surname><given-names>F.</given-names></name><etal></etal></person-group><article-title>Guidelines for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations</article-title><source><italic>Clinical Nutrition</italic></source><year>2012</year><volume>31</volume><issue>6</issue><fpage>801</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2012.08.012</pub-id><pub-id pub-id-type="other">2-s2.0-84870252840</pub-id><pub-id pub-id-type="pmid">23062720</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansdottir</surname><given-names>V.</given-names></name><name><surname>Philip</surname><given-names>J.</given-names></name><name><surname>Olsen</surname><given-names>M. F.</given-names></name><name><surname>Eduard</surname><given-names>C.</given-names></name><name><surname>Houltz</surname><given-names>E.</given-names></name><name><surname>Ricksten</surname><given-names>S. E.</given-names></name></person-group><article-title>Thoracic epidural versus intravenous patient-controlled analgesia after cardiac surgery: a randomized controlled trial on length of hospital stay and patient-perceived quality of recovery</article-title><source><italic>Anesthesiology</italic></source><year>2006</year><volume>104</volume><issue>1</issue><fpage>142</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">16394700</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Jin</surname><given-names>S.</given-names></name><name><surname>Niu</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Fu</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name></person-group><article-title>A comparison of the analgesia efficacy and side effects of paravertebral compared with epidural blockade for thoracotomy: an updated meta-analysis</article-title><source><italic>PloS One</italic></source><year>2014</year><volume>9</volume><issue>5</issue><pub-id pub-id-type="publisher-id">e96233</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0096233</pub-id><pub-id pub-id-type="other">2-s2.0-84900424750</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupersztych-Hagege</surname><given-names>E.</given-names></name><name><surname>Dubuisson</surname><given-names>E.</given-names></name><name><surname>Szekely</surname><given-names>B.</given-names></name><etal></etal></person-group><article-title>Epidural hematoma and abscess related to thoracic epidural analgesia: a single-center study of 2,907 patients who underwent lung surgery</article-title><source><italic>Journal of Cardiothoracic and Vascular Anesthesia</italic></source><year>2017</year><volume>31</volume><issue>2</issue><fpage>446</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1053/j.jvca.2016.07.022</pub-id><pub-id pub-id-type="other">2-s2.0-84992028920</pub-id><pub-id pub-id-type="pmid">27720493</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borzellino</surname><given-names>G.</given-names></name><name><surname>Francis</surname><given-names>N. K.</given-names></name><name><surname>Chapuis</surname><given-names>O.</given-names></name><name><surname>Krastinova</surname><given-names>E.</given-names></name><name><surname>Dyevre</surname><given-names>V.</given-names></name><name><surname>Genna</surname><given-names>M.</given-names></name></person-group><article-title>Role of epidural analgesia within an ERAS program after laparoscopic colorectal surgery: a review and meta-analysis of randomised controlled studies</article-title><source><italic>Surgery Research and Practice</italic></source><year>2016</year><volume>2016</volume><fpage>9</fpage><pub-id pub-id-type="publisher-id">7543684</pub-id><pub-id pub-id-type="doi">10.1155/2016/7543684</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Abdein Mohamed</surname><given-names>A. Z.</given-names></name></person-group><article-title>Assessment of the analgesic potency of ropivacaine 0.2% versus ropivacaine 0.5% in transversus abdominis plane block after cesarean delivery</article-title><source><italic>Egyptian Journal of Anaesthesia</italic></source><year>2016</year><volume>32</volume><issue>3</issue><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.egja.2016.03.003</pub-id><pub-id pub-id-type="other">2-s2.0-84975780195</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henshaw</surname><given-names>D. S.</given-names></name><name><surname>Baker</surname><given-names>M. L.</given-names></name><name><surname>Weller</surname><given-names>R. S.</given-names></name><name><surname>Reynolds</surname><given-names>J. W.</given-names></name><name><surname>Jaffe</surname><given-names>J. D.</given-names></name></person-group><article-title>Transversus abdominis plane block as the primary anesthetic for peritoneal dialysis catheter surgery</article-title><source><italic>Journal of Clinical Anesthesia</italic></source><year>2016</year><volume>31</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.jclinane.2016.01.028</pub-id><pub-id pub-id-type="other">2-s2.0-84963629111</pub-id><pub-id pub-id-type="pmid">27185705</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelsalam</surname><given-names>K.</given-names></name><name><surname>Mohamdin</surname><given-names>O. W.</given-names></name></person-group><article-title>Ultrasound-guided rectus sheath and transversus abdominis plane blocks for perioperative analgesia in upper abdominal surgery: a randomized controlled study</article-title><source><italic>Saudi Journal of Anaesthesia</italic></source><year>2016</year><volume>10</volume><issue>1</issue><fpage>25</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.4103/1658-354x.169470</pub-id><pub-id pub-id-type="other">2-s2.0-84955580795</pub-id><pub-id pub-id-type="pmid">26955306</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>N.</given-names></name><name><surname>Long</surname><given-names>X.</given-names></name><name><surname>Lujan-Hernandez</surname><given-names>J. R.</given-names></name><name><surname>Succar</surname><given-names>J.</given-names></name><name><surname>Xin</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Transversus abdominis-plane block versus local anesthetic wound infiltration in lower abdominal surgery: a systematic review and meta-analysis of randomized controlled trials</article-title><source><italic>BMC Anesthesiology</italic></source><year>2014</year><volume>14</volume><issue>1</issue><fpage>p. 121</fpage><pub-id pub-id-type="doi">10.1186/1471-2253-14-121</pub-id><pub-id pub-id-type="other">2-s2.0-84924030005</pub-id><pub-id pub-id-type="pmid">25580086</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnerty</surname><given-names>O.</given-names></name><name><surname>Sharkey</surname><given-names>A.</given-names></name><name><surname>Mc Donnell</surname><given-names>J. G.</given-names></name></person-group><article-title>Transversus abdominis plane block for abdominal surgery</article-title><source><italic>Minerva Anestesiologica</italic></source><year>2013</year><volume>79</volume><issue>4</issue><fpage>1415</fpage><lpage>1422</lpage><pub-id pub-id-type="doi">10.1007/s40140-013-0034-5</pub-id><pub-id pub-id-type="pmid">23839315</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halaszynski</surname><given-names>T. M.</given-names></name></person-group><article-title>Ultrasound brachial plexus anesthesia and analgesia for upper extremity surgery: essentials of our current understanding</article-title><source><italic>Current Opinion in Anaesthesiology</italic></source><year>2011</year><volume>24</volume><issue>5</issue><fpage>581</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1097/aco.0b013e32834aca03</pub-id><pub-id pub-id-type="other">2-s2.0-80052679895</pub-id><pub-id pub-id-type="pmid">21897215</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albrecht</surname><given-names>E.</given-names></name><name><surname>Kern</surname><given-names>C.</given-names></name><name><surname>Kirkham</surname><given-names>K. R.</given-names></name></person-group><article-title>A systematic review and meta-analysis of perineural dexamethasone for peripheral nerve blocks</article-title><source><italic>Anaesthesia</italic></source><year>2015</year><volume>70</volume><issue>1</issue><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1111/anae.12823</pub-id><pub-id pub-id-type="other">2-s2.0-84916894070</pub-id><pub-id pub-id-type="pmid">25123271</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>J. D.</given-names></name><name><surname>Le</surname><given-names>N. V.</given-names></name><name><surname>Grant</surname><given-names>S.</given-names></name><name><surname>Bjorksten</surname><given-names>A.</given-names></name><name><surname>Hebbard</surname><given-names>P.</given-names></name><name><surname>Royse</surname><given-names>C.</given-names></name></person-group><article-title>Symptomatic local anaesthetic toxicity and plasma ropivacaine concentrations after transversus abdominis plane block for Caesarean section</article-title><source><italic>British Journal of Anaesthesia</italic></source><year>2013</year><volume>110</volume><issue>6</issue><fpage>996</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1093/bja/aet015</pub-id><pub-id pub-id-type="other">2-s2.0-84878309822</pub-id><pub-id pub-id-type="pmid">23454825</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdallah</surname><given-names>F. W.</given-names></name><name><surname>Chan</surname><given-names>V. W.</given-names></name><name><surname>Brull</surname><given-names>R.</given-names></name></person-group><article-title>Transversus abdominis plane block: a systematic review</article-title><source><italic>Regional Anesthesia and Pain Medicine</italic></source><year>2012</year><volume>37</volume><issue>2</issue><fpage>193</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1097/aap.0b013e3182429531</pub-id><pub-id pub-id-type="other">2-s2.0-84859769107</pub-id><pub-id pub-id-type="pmid">22286518</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Golan</surname><given-names>D. E.</given-names></name></person-group><source><italic>Priciples of Pharmacology: The Pathophysiologic Basis of Drug Therapy</italic></source><year>2008</year><publisher-loc>Baltimore, MD, USA</publisher-loc><publisher-name>Lippincott Williams &amp;Wilkins</publisher-name></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinatra</surname><given-names>R.</given-names></name></person-group><article-title>Role of COX-2 inhibitors in the evolution of acute pain management</article-title><source><italic>Journal of Pain and Symptom Management</italic></source><year>2002</year><volume>24</volume><issue>1</issue><fpage>S18</fpage><lpage>S27</lpage><pub-id pub-id-type="doi">10.1016/s0885-3924(02)00410-4</pub-id><pub-id pub-id-type="other">2-s2.0-0036666189</pub-id><pub-id pub-id-type="pmid">12204484</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>K.</given-names></name><name><surname>Fukusaki</surname><given-names>M.</given-names></name><name><surname>Ando</surname><given-names>Y.</given-names></name><etal></etal></person-group><article-title>Preoperative administration of intravenous flurbiprofen axetil reduces postoperative pain for spinal fusion surgery</article-title><source><italic>Journal of Anesthesia</italic></source><year>2006</year><volume>20</volume><issue>2</issue><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s00540-006-0389-6</pub-id><pub-id pub-id-type="other">2-s2.0-33646005810</pub-id><pub-id pub-id-type="pmid">16633764</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitot</surname><given-names>V.</given-names></name><name><surname>Beaussier</surname><given-names>M.</given-names></name></person-group><article-title>NSAIDs and risk of anastomotic leakage after gastrointestinal surgery</article-title><source><italic>Presse Medicale</italic></source><year>2014</year><volume>43</volume><fpage>633</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.lpm.2013.09.017</pub-id><pub-id pub-id-type="other">2-s2.0-84902546296</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>M.</given-names></name></person-group><article-title>Postoperative non-steroidal anti-inflammatory drugs and colorectal anastomotic leakage. NSAIDs and anastomotic leakage</article-title><source><italic>Danish Medical Journal</italic></source><year>2012</year><volume>59</volume><issue>3</issue><fpage>p. B4420</fpage><pub-id pub-id-type="pmid">22381097</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhangu</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>P.</given-names></name><name><surname>Fitzgerald</surname><given-names>J. E.</given-names></name><name><surname>Slesser</surname><given-names>A.</given-names></name><name><surname>Tekkis</surname><given-names>P.</given-names></name></person-group><article-title>Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies</article-title><source><italic>World Journal of Surgery</italic></source><year>2014</year><volume>38</volume><issue>9</issue><fpage>2247</fpage><lpage>2257</lpage><pub-id pub-id-type="doi">10.1007/s00268-014-2531-1</pub-id><pub-id pub-id-type="other">2-s2.0-84905677623</pub-id><pub-id pub-id-type="pmid">24682313</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihara</surname><given-names>R.</given-names></name><name><surname>Soen</surname><given-names>M.</given-names></name><name><surname>Kusaka</surname><given-names>H.</given-names></name><etal></etal></person-group><article-title>Effect of continuous intravenous infusion of flurbiprofen axetil and tramadol hydrochloride for postoperative pain management of laparoscopic colectomy</article-title><source><italic>Masui the Japanese Journal of Anesthesiology</italic></source><year>2011</year><volume>60</volume><fpage>1364</fpage><lpage>1369</lpage><pub-id pub-id-type="pmid">22256576</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellmauer</surname><given-names>S.</given-names></name></person-group><article-title>Sufentanil. An alternative to fentanyl/alfentanil?</article-title><source><italic>Der Anaesthesist</italic></source><year>1994</year><volume>43</volume><issue>3</issue><fpage>143</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1007/s001010050043</pub-id><pub-id pub-id-type="other">2-s2.0-0028197069</pub-id><pub-id pub-id-type="pmid">8179164</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J. C.</given-names></name><name><surname>Smith</surname><given-names>E. R.</given-names></name><name><surname>Cahill</surname><given-names>M.</given-names></name><name><surname>Cohen</surname><given-names>R.</given-names></name><name><surname>Fishman</surname><given-names>J. B.</given-names></name></person-group><article-title>The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine</article-title><source><italic>Life Sciences</italic></source><year>1993</year><volume>52</volume><issue>4</issue><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(93)90152-s</pub-id><pub-id pub-id-type="other">2-s2.0-0027452629</pub-id><pub-id pub-id-type="pmid">8093631</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawal</surname><given-names>N.</given-names></name><name><surname>Wennhager</surname><given-names>M.</given-names></name></person-group><article-title>Influence of perioperative nalbuphine and fentanyl on postoperative respiration and analgesia</article-title><source><italic>Acta Anaesthesiologica Scandinavica</italic></source><year>1990</year><volume>34</volume><issue>3</issue><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.1990.tb03069.x</pub-id><pub-id pub-id-type="other">2-s2.0-0025218462</pub-id><pub-id pub-id-type="pmid">2111627</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flacke</surname><given-names>J. W.</given-names></name><name><surname>Bloor</surname><given-names>B. C.</given-names></name><name><surname>Kripke</surname><given-names>B. J.</given-names></name><etal></etal></person-group><article-title>Comparison of morphine, meperidine, fentanyl, and sufentanil in balanced anesthesia: a double-blind study</article-title><source><italic>Anesthesia &amp; Analgesia</italic></source><year>1985</year><volume>64</volume><issue>9</issue><fpage>897</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1213/00000539-198509000-00009</pub-id><pub-id pub-id-type="pmid">2862810</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riviere</surname><given-names>P. J.</given-names></name></person-group><article-title>Peripheral kappa-opioid agonists for visceral pain</article-title><source><italic>British Journal of Pharmacology</italic></source><year>2004</year><volume>141</volume><issue>8</issue><fpage>1331</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0705763</pub-id><pub-id pub-id-type="other">2-s2.0-2442472275</pub-id><pub-id pub-id-type="pmid">15051626</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>T. J.</given-names></name><name><surname>Meyer</surname><given-names>T. A.</given-names></name><name><surname>Apfel</surname><given-names>C. C.</given-names></name><etal></etal></person-group><article-title>Society for ambulatory anesthesia guidelines for the management of postoperative nausea and vomiting</article-title><source><italic>Anesthesia &amp; Analgesia</italic></source><year>2007</year><volume>105</volume><issue>6</issue><fpage>1615</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1213/01.ane.0000295230.55439.f4</pub-id><pub-id pub-id-type="other">2-s2.0-36549017689</pub-id><pub-id pub-id-type="pmid">18042859</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jannuzzi</surname><given-names>R. G.</given-names></name></person-group><article-title>Nalbuphine for treatment of opioid-induced pruritus: a systematic review of literature</article-title><source><italic>Clinical Journal of Pain</italic></source><year>2016</year><volume>32</volume><issue>1</issue><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1097/AJP.0000000000000211</pub-id><pub-id pub-id-type="other">2-s2.0-84951786994</pub-id><pub-id pub-id-type="pmid">26650717</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J. J.</given-names></name><name><surname>Ho</surname><given-names>S. T.</given-names></name><name><surname>Tzeng</surname><given-names>J. I.</given-names></name></person-group><article-title>Comparison of intravenous nalbuphine infusion versus naloxone in the prevention of epidural morphine-related side effects</article-title><source><italic>Regional Anesthesia and Pain Medicine</italic></source><year>1998</year><volume>23</volume><issue>5</issue><fpage>479</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1097/00115550-199823050-00009</pub-id><pub-id pub-id-type="pmid">9773701</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>J. L.</given-names></name><name><surname>Hagemann</surname><given-names>T. M.</given-names></name></person-group><article-title>Use of pure opioid antagonists for management of opioid-induced pruritus</article-title><source><italic>American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists</italic></source><year>2011</year><volume>68</volume><issue>15</issue><fpage>1419</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.2146/ajhp100475</pub-id><pub-id pub-id-type="other">2-s2.0-79961110881</pub-id><pub-id pub-id-type="pmid">21785031</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarzyna</surname><given-names>D.</given-names></name><name><surname>Jungquist</surname><given-names>C. R.</given-names></name><name><surname>Pasero</surname><given-names>C.</given-names></name><etal></etal></person-group><article-title>American society for pain management nursing guidelines on monitoring for opioid-induced sedation and respiratory depression</article-title><source><italic>Pain Management Nursing: Official Journal of the American Society of Pain Management Nurses</italic></source><year>2011</year><volume>12</volume><issue>3</issue><fpage>118.e10</fpage><lpage>145.e10</lpage><pub-id pub-id-type="doi">10.1016/j.pmn.2011.06.008</pub-id><pub-id pub-id-type="other">2-s2.0-80052408237</pub-id><pub-id pub-id-type="pmid">21893302</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>N. L.</given-names></name><name><surname>Choi</surname><given-names>K. C.</given-names></name><name><surname>Affleck</surname><given-names>P. J.</given-names></name><etal></etal></person-group><article-title>Analgesia, pruritus, and ventilation exhibit a dose-response relationship in parturients receiving intrathecal fentanyl during labor</article-title><source><italic>Anesthesia &amp; Analgesia</italic></source><year>1999</year><volume>89</volume><issue>2</issue><fpage>378</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1097/00000539-199908000-00024</pub-id><pub-id pub-id-type="other">2-s2.0-0032793521</pub-id><pub-id pub-id-type="pmid">10439751</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow of patients in the study.</p></caption><graphic xlink:href="PRM2018-3637013.001"></graphic></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Basic characteristics of patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Group S</th><th align="center" rowspan="1" colspan="1">Group L</th><th align="center" rowspan="1" colspan="1">Group M</th><th align="center" rowspan="1" colspan="1">Group H</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (male/female)</td><td align="center" rowspan="1" colspan="1">30/10</td><td align="center" rowspan="1" colspan="1">29/11</td><td align="center" rowspan="1" colspan="1">27/11</td><td align="center" rowspan="1" colspan="1">28/12</td><td align="center" rowspan="1" colspan="1">0.279</td></tr><tr><td align="left" rowspan="1" colspan="1">ASA (I/II/III)</td><td align="center" rowspan="1" colspan="1">3/27/10</td><td align="center" rowspan="1" colspan="1">5/34/1</td><td align="center" rowspan="1" colspan="1">4/23/11</td><td align="center" rowspan="1" colspan="1">2/29/9</td><td align="center" rowspan="1" colspan="1">0.070</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, mean (SD) (yr)</td><td align="center" rowspan="1" colspan="1">71.40 (4.65)</td><td align="center" rowspan="1" colspan="1">71.15 (5.60)</td><td align="center" rowspan="1" colspan="1">70.15 (4.46)</td><td align="center" rowspan="1" colspan="1">71.63 (5.79)</td><td align="center" rowspan="1" colspan="1">0.592</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, mean (SD) (kg)</td><td align="center" rowspan="1" colspan="1">59.60 (9.39)</td><td align="center" rowspan="1" colspan="1">57.53 (8.39)</td><td align="center" rowspan="1" colspan="1">57.85 (10.19)</td><td align="center" rowspan="1" colspan="1">60.93 (11.21)</td><td align="center" rowspan="1" colspan="1">0.377</td></tr><tr><td align="left" rowspan="1" colspan="1">Height, mean (SD) (m)</td><td align="center" rowspan="1" colspan="1">1.65 (0.68)</td><td align="center" rowspan="1" colspan="1">1.65 (0.71)</td><td align="center" rowspan="1" colspan="1">1.63 (0.70)</td><td align="center" rowspan="1" colspan="1">1.63 (0.85)</td><td align="center" rowspan="1" colspan="1">0.627</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, mean (SD)</td><td align="center" rowspan="1" colspan="1">21.81 (2.87)</td><td align="center" rowspan="1" colspan="1">21.25 (2.71)</td><td align="center" rowspan="1" colspan="1">21.68 (3.77)</td><td align="center" rowspan="1" colspan="1">22.83 (3.66)</td><td align="center" rowspan="1" colspan="1">0.179</td></tr><tr><td align="left" rowspan="1" colspan="1">MAP, mean (SD) (mmHg)</td><td align="center" rowspan="1" colspan="1">105.2 (12.4)</td><td align="center" rowspan="1" colspan="1">102.1 (13.0)</td><td align="center" rowspan="1" colspan="1">99.2 (15.5)</td><td align="center" rowspan="1" colspan="1">103.6 (14.2)</td><td align="center" rowspan="1" colspan="1">0.257</td></tr></tbody></table><table-wrap-foot><fn><p>BMI = body mass index.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Characteristics of surgery and anesthesia during operation and recovery.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Group S</th><th align="center" rowspan="1" colspan="1">Group L</th><th align="center" rowspan="1" colspan="1">Group M</th><th align="center" rowspan="1" colspan="1">Group H</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Anesthesia duration (min)</td><td align="center" rowspan="1" colspan="1">155.80 (48.86)</td><td align="center" rowspan="1" colspan="1">162.83 (49.79)</td><td align="center" rowspan="1" colspan="1">169.40 (57.75)</td><td align="center" rowspan="1" colspan="1">172.78 (54.66)</td><td align="center" rowspan="1" colspan="1">0.493</td></tr><tr><td align="left" rowspan="1" colspan="1">Operation time (min)</td><td align="center" rowspan="1" colspan="1">134.18 (45.73)</td><td align="center" rowspan="1" colspan="1">139.60 (46.37)</td><td align="center" rowspan="1" colspan="1">144.35 (52.60)</td><td align="center" rowspan="1" colspan="1">153.08 (56.58)</td><td align="center" rowspan="1" colspan="1">0.392</td></tr><tr><td align="left" rowspan="1" colspan="1">Sulfentanyl (<italic>μ</italic>g)</td><td align="center" rowspan="1" colspan="1">48.50 (12.51)</td><td align="center" rowspan="1" colspan="1">46.58 (9.75)</td><td align="center" rowspan="1" colspan="1">49.69 (10.16)</td><td align="center" rowspan="1" colspan="1">50.56 (12.50)</td><td align="center" rowspan="1" colspan="1">0.427</td></tr><tr><td align="left" rowspan="1" colspan="1">Crystalloid fluid (ml)</td><td align="center" rowspan="1" colspan="1">1135.00 (395.84)</td><td align="center" rowspan="1" colspan="1">1166.67 (555.04)</td><td align="center" rowspan="1" colspan="1">1150.00 (451.78)</td><td align="center" rowspan="1" colspan="1">1198.75 (415.48)</td><td align="center" rowspan="1" colspan="1">0.956</td></tr><tr><td align="left" rowspan="1" colspan="1">Colloid fluid (ml)</td><td align="center" rowspan="1" colspan="1">510.00 (271.79)</td><td align="center" rowspan="1" colspan="1">578.95 (184.77)</td><td align="center" rowspan="1" colspan="1">512.50 (232.80)</td><td align="center" rowspan="1" colspan="1">487.50 (306.50)</td><td align="center" rowspan="1" colspan="1">0.435</td></tr><tr><td align="left" rowspan="1" colspan="1">Awake time (min)</td><td align="center" rowspan="1" colspan="1">30.51 (23.93)</td><td align="center" rowspan="1" colspan="1">30.35 (20.00)</td><td align="center" rowspan="1" colspan="1">35.65 (27.93)</td><td align="center" rowspan="1" colspan="1">30.40 (20.71)</td><td align="center" rowspan="1" colspan="1">0.682</td></tr><tr><td align="left" rowspan="1" colspan="1">Extubation time (min)</td><td align="center" rowspan="1" colspan="1">28.28 (18.60)</td><td align="center" rowspan="1" colspan="1">28.88 (17.22)</td><td align="center" rowspan="1" colspan="1">31.98 (19.33)</td><td align="center" rowspan="1" colspan="1">28.48 (20.50)</td><td align="center" rowspan="1" colspan="1">0.801</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>The VAS pain score and effective pressing numbers of PCIA machine during the observation period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Observational period</th><th align="center" rowspan="1" colspan="1">Group S</th><th align="center" rowspan="1" colspan="1">Group L</th><th align="center" rowspan="1" colspan="1">Group M</th><th align="center" rowspan="1" colspan="1">Group H</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">VAS pain score</td><td align="center" rowspan="1" colspan="1">0–6 h</td><td align="center" rowspan="1" colspan="1">1.05 (1.449)</td><td align="center" rowspan="1" colspan="1">0.95 (1.011)</td><td align="center" rowspan="1" colspan="1">0.98 (1.223)</td><td align="center" rowspan="1" colspan="1">0.98 (1.365)</td><td align="center" rowspan="1" colspan="1">0.988</td></tr><tr><td align="center" rowspan="1" colspan="1">6–12 h</td><td align="center" rowspan="1" colspan="1">1.40 (1.598)</td><td align="center" rowspan="1" colspan="1">1.00 (0.987)</td><td align="center" rowspan="1" colspan="1">1.05 (1.260)</td><td align="center" rowspan="1" colspan="1">1.23 (1.423)</td><td align="center" rowspan="1" colspan="1">0.527</td></tr><tr><td align="center" rowspan="1" colspan="1">12–24 h</td><td align="center" rowspan="1" colspan="1">1.75 (1.721)</td><td align="center" rowspan="1" colspan="1">1.28 (0.176)</td><td align="center" rowspan="1" colspan="1">1.18 (1.130)</td><td align="center" rowspan="1" colspan="1">1.08 (1.403)</td><td align="center" rowspan="1" colspan="1">0.084</td></tr><tr><td align="center" rowspan="1" colspan="1">24–48 h</td><td align="center" rowspan="1" colspan="1">1.68 (1.685)</td><td align="center" rowspan="1" colspan="1">1.30 (1.305)</td><td align="center" rowspan="1" colspan="1">1.18 (1.238)</td><td align="center" rowspan="1" colspan="1">1.20 (1.418)</td><td align="center" rowspan="1" colspan="1">0.363</td></tr><tr><td align="left" rowspan="4" colspan="1">Effective pressing numbers</td><td align="center" rowspan="1" colspan="1">0–6 h</td><td align="center" rowspan="1" colspan="1">0.55 (1.108)</td><td align="center" rowspan="1" colspan="1">0.60 (1.008)</td><td align="center" rowspan="1" colspan="1">0.88 (1.453)</td><td align="center" rowspan="1" colspan="1">0.83 (1.708)</td><td align="center" rowspan="1" colspan="1">0.620</td></tr><tr><td align="center" rowspan="1" colspan="1">6–12 h</td><td align="center" rowspan="1" colspan="1">0.75 (1.463)</td><td align="center" rowspan="1" colspan="1">0.58 (1.357)</td><td align="center" rowspan="1" colspan="1">1.00 (1.617)</td><td align="center" rowspan="1" colspan="1">0.65 (1.099)</td><td align="center" rowspan="1" colspan="1">0.558</td></tr><tr><td align="center" rowspan="1" colspan="1">12–24 h</td><td align="center" rowspan="1" colspan="1">1.95 (5.228)</td><td align="center" rowspan="1" colspan="1">1.18 (2.531)</td><td align="center" rowspan="1" colspan="1">1.30 (2.151)</td><td align="center" rowspan="1" colspan="1">0.73 (1.633)</td><td align="center" rowspan="1" colspan="1">0.399</td></tr><tr><td align="center" rowspan="1" colspan="1">24–48 h</td><td align="center" rowspan="1" colspan="1">1.28 (1.679)</td><td align="center" rowspan="1" colspan="1">1.30 (2.775)</td><td align="center" rowspan="1" colspan="1">1.03 (1.459)</td><td align="center" rowspan="1" colspan="1">0.55 (0.783)</td><td align="center" rowspan="1" colspan="1">0.225</td></tr></tbody></table><table-wrap-foot><fn><p>VAS = visual analogue scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>The incidence and severity of postoperative nausea and vomiting during the observation period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Group S</th><th align="center" rowspan="1" colspan="1">Group L</th><th align="center" rowspan="1" colspan="1">Group M</th><th align="center" rowspan="1" colspan="1">Group H</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>1</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>2</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>3</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Incidence (n/N)</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" rowspan="1" colspan="1">0–6 h</td><td align="center" rowspan="1" colspan="1">9 (40)</td><td align="center" rowspan="1" colspan="1">0 (40)</td><td align="center" rowspan="1" colspan="1">2 (38)</td><td align="center" rowspan="1" colspan="1">2 (40)</td><td align="center" rowspan="1" colspan="1">0.238</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" rowspan="1" colspan="1">6–12 h</td><td align="center" rowspan="1" colspan="1">9 (40)</td><td align="center" rowspan="1" colspan="1">0 (40)</td><td align="center" rowspan="1" colspan="1">2 (38)</td><td align="center" rowspan="1" colspan="1">1 (40)</td><td align="center" rowspan="1" colspan="1">0.213</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" rowspan="1" colspan="1">12–24 h</td><td align="center" rowspan="1" colspan="1">7 (40)</td><td align="center" rowspan="1" colspan="1">1 (40)</td><td align="center" rowspan="1" colspan="1">3 (38)</td><td align="center" rowspan="1" colspan="1">3 (40)</td><td align="center" rowspan="1" colspan="1">0.238</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" rowspan="1" colspan="1">24–48 h</td><td align="center" rowspan="1" colspan="1">7 (40)</td><td align="center" rowspan="1" colspan="1">0 (40)</td><td align="center" rowspan="1" colspan="1">2 (38)</td><td align="center" rowspan="1" colspan="1">3 (40)</td><td align="center" rowspan="1" colspan="1">0.213</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" rowspan="1" colspan="1">Severity (0/1/2/3)</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">—</td></tr><tr><td align="left" rowspan="1" colspan="1">0–6 h</td><td align="center" rowspan="1" colspan="1">31/7/1/1</td><td align="center" rowspan="1" colspan="1">40/0/0/0</td><td align="center" rowspan="1" colspan="1">36/1/1/0</td><td align="center" rowspan="1" colspan="1">38/1/0/1</td><td align="center" rowspan="1" colspan="1">0.002<sup>∗</sup></td><td align="center" rowspan="1" colspan="1">0.002<sup>∗</sup></td><td align="center" rowspan="1" colspan="1">0.033</td><td align="center" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" rowspan="1" colspan="1">6–12 h</td><td align="center" rowspan="1" colspan="1">31/7/1/1</td><td align="center" rowspan="1" colspan="1">40/0/0/0</td><td align="center" rowspan="1" colspan="1">36/1/1/0</td><td align="center" rowspan="1" colspan="1">39/1/0/0</td><td align="center" rowspan="1" colspan="1">0.001<sup>∗</sup></td><td align="center" rowspan="1" colspan="1">0.002<sup>∗</sup></td><td align="center" rowspan="1" colspan="1">0.033</td><td align="center" rowspan="1" colspan="1">0.007<sup>∗</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">12–24 h</td><td align="center" rowspan="1" colspan="1">33/6/1/0</td><td align="center" rowspan="1" colspan="1">39/1/0/0</td><td align="center" rowspan="1" colspan="1">35/2/1/0</td><td align="center" rowspan="1" colspan="1">37/3/0/0</td><td align="center" rowspan="1" colspan="1">0.121</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td></tr><tr><td align="left" rowspan="1" colspan="1">24–48 h</td><td align="center" rowspan="1" colspan="1">33/6/1/0</td><td align="center" rowspan="1" colspan="1">40/0/0/0</td><td align="center" rowspan="1" colspan="1">36/1/1/0</td><td align="center" rowspan="1" colspan="1">37/3/0/0</td><td align="center" rowspan="1" colspan="1">0.029<sup>∗</sup></td><td align="center" rowspan="1" colspan="1">0.006<sup>∗</sup></td><td align="center" rowspan="1" colspan="1">0.103</td><td align="center" rowspan="1" colspan="1">0.171</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic>p</italic>1, Group L versus Group S; <italic>p</italic>2, Group M versus Group S; <italic>p</italic>3, Group H versus Group S; <sup>∗</sup>statistically significant (<italic>p</italic> &lt; 0.01).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>The records of Ramsay during the observation period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Group S</th><th align="center" rowspan="1" colspan="1">Group L</th><th align="center" rowspan="1" colspan="1">Group M</th><th align="center" rowspan="1" colspan="1">Group H</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">0–6 h (1/2/3/4/5)</td><td align="center" rowspan="1" colspan="1">1/34/5/0/0</td><td align="center" rowspan="1" colspan="1">1/29/10/0/0</td><td align="center" rowspan="1" colspan="1">0/29/8/1/0</td><td align="center" rowspan="1" colspan="1">3/25/11/1/0</td><td align="center" rowspan="1" colspan="1">0.467</td></tr><tr><td align="left" rowspan="1" colspan="1">6–12 h (1/2/3/4/5)</td><td align="center" rowspan="1" colspan="1">1/34/5/0/0</td><td align="center" rowspan="1" colspan="1">1/32/7/0/0</td><td align="center" rowspan="1" colspan="1">0/32/5/1/0</td><td align="center" rowspan="1" colspan="1">3/26/11/0/0</td><td align="center" rowspan="1" colspan="1">0.739</td></tr><tr><td align="left" rowspan="1" colspan="1">12–24 h (1/2/3/4/5)</td><td align="center" rowspan="1" colspan="1">1/37/2/0/0</td><td align="center" rowspan="1" colspan="1">0/36/4/0/0</td><td align="center" rowspan="1" colspan="1">0/34/4/0/0</td><td align="center" rowspan="1" colspan="1">2/28/9/0/1</td><td align="center" rowspan="1" colspan="1">0.170</td></tr><tr><td align="left" rowspan="1" colspan="1">24–48 h (0/1/2/3/4/5)</td><td align="center" rowspan="1" colspan="1">0/1/38/1/0/0</td><td align="center" rowspan="1" colspan="1">1/0/35/4/0/0</td><td align="center" rowspan="1" colspan="1">0/1/33/4/0/0</td><td align="center" rowspan="1" colspan="1">0/2/29/8/0/1</td><td align="center" rowspan="1" colspan="1">0.185</td></tr></tbody></table></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Postoperative short-time recovery.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Group S</th><th align="center" rowspan="1" colspan="1">Group L</th><th align="center" rowspan="1" colspan="1">Group M</th><th align="center" rowspan="1" colspan="1">Group H</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Leaving bed activity, POD</td><td align="center" rowspan="1" colspan="1">3.63 (1.675)</td><td align="center" rowspan="1" colspan="1">3.68 (1.366)</td><td align="center" rowspan="1" colspan="1">3.70 (1.588)</td><td align="center" rowspan="1" colspan="1">3.73 (1.694)</td><td align="center" rowspan="1" colspan="1">0.988</td></tr><tr><td align="left" rowspan="1" colspan="1">Intestinal movement, POD</td><td align="center" rowspan="1" colspan="1">3.83 (1.338)</td><td align="center" rowspan="1" colspan="1">3.68 (1.185)</td><td align="center" rowspan="1" colspan="1">3.85 (1.145)</td><td align="center" rowspan="1" colspan="1">3.63 (1.079)</td><td align="center" rowspan="1" colspan="1">0.527</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative stay in hospital, POD</td><td align="center" rowspan="1" colspan="1">11.18 (3.071)</td><td align="center" rowspan="1" colspan="1">10.85 (3.289)</td><td align="center" rowspan="1" colspan="1">10.76 (3.467)</td><td align="center" rowspan="1" colspan="1">11.91 (4.957)</td><td align="center" rowspan="1" colspan="1">0.084</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospitalization expenses, ¥</td><td align="center" rowspan="1" colspan="1">45,030 (10,949)</td><td align="center" rowspan="1" colspan="1">43,896 (11,572)</td><td align="center" rowspan="1" colspan="1">47,216 (16,141)</td><td align="center" rowspan="1" colspan="1">44,291 (9,532)</td><td align="center" rowspan="1" colspan="1">0.363</td></tr></tbody></table><table-wrap-foot><fn><p>POD = postoperative day.</p></fn></table-wrap-foot></table-wrap></floats-group></article>